Clinical Trial

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2022 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Trial Details
NCT Number NCT05552937
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions DLBCL
Enrollment 50 participants
Start Date 2021-09-06
Primary Completion 2025-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2022-09-23